NASDAQ:ENOB Enochian Biosciences (ENOB) Stock Forecast, Price & News $0.78 -0.04 (-4.89%) (As of 01:45 PM ET) Add Compare Share Share Today's Range$0.78▼$0.8850-Day Range$0.82▼$1.3052-Week Range$0.72▼$4.20Volume31,577 shsAverage Volume51,989 shsMarket Capitalization$45.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability About Enochian Biosciences (NASDAQ:ENOB) StockEnochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.Read More Receive ENOB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enochian Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ENOB Stock News HeadlinesMay 31, 2023 | americanbankingnews.comEnochian Biosciences Inc. (NASDAQ:ENOB) Short Interest UpdateMay 18, 2023 | americanbankingnews.comEnochian Biosciences Inc. (NASDAQ:ENOB) Sees Large Decrease in Short InterestJune 2, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.April 15, 2023 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Enochian Biosciences Inc. (ENOB)April 3, 2023 | finance.yahoo.comEnochian BioSciences’ CEO Letter to ShareholdersMarch 29, 2023 | finance.yahoo.comEnochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading ResearcherMarch 13, 2023 | finanznachrichten.deEnochian BioSciences, Inc.: Enochian BioSciences Achieves Full Compliance with NASDAQ Filing RequirementsMarch 13, 2023 | msn.comEnochian BioSciences regains Nasdaq compliance by filing pending reportsJune 2, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. March 13, 2023 | finance.yahoo.comEnochian BioSciences Achieves Full Compliance with NASDAQ Filing RequirementsFebruary 23, 2023 | msn.comEnochian gets Nasdaq listing deficiency notice for not filing 10-QFebruary 23, 2023 | finance.yahoo.comEnochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022January 19, 2023 | reuters.comENOB.O - | Stock Price & Latest News | ReutersNovember 30, 2022 | seekingalpha.comEnochian gets Nasdaq notice for delaying crucial filingsNovember 30, 2022 | finance.yahoo.comEnochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022October 24, 2022 | finance.yahoo.comBiotech Co-Founder, Facing Murder-for-Hire Charges, Accused of Fabricating DataOctober 24, 2022 | finance.yahoo.comEnochian BioSciences Forges Ahead With Focused Approach, Promising FutureOctober 21, 2022 | finance.yahoo.comEnochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-KOctober 19, 2022 | finanznachrichten.deEnochian BioSciences, Inc.: Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology PlatformOctober 17, 2022 | finance.yahoo.comEnochian BioSciences Awarded U.S. Patent For Its Promising Oncology PlatformOctober 13, 2022 | finance.yahoo.comEnochian Biosciences, Inc. (ENOB)September 26, 2022 | benzinga.comFINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the FirmSeptember 24, 2022 | tmcnet.comENOCHIAN DEADLINE ALERT: Bragar Eagel & Squire, P.C.September 23, 2022 | benzinga.comEdelson Lechtzin LLP Reminds Enochian Biosciences, Inc. Investors of the Impending Lead Plaintiff DeadlineSeptember 20, 2022 | benzinga.comCLASS ACTION UPDATE for ENOB, MNSO and PLTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersSeptember 19, 2022 | benzinga.comSHAREHOLDER DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the FirmSeptember 16, 2022 | markets.businessinsider.comPre-market Movers: ATXG, FWBI, IDYA, ENOB, LUCY…See More Headlines ENOB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENOB Company Calendar Today6/02/2023Next Earnings (Estimated)6/02/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENOB CUSIPN/A CIK1527728 Webwww.enochianbio.com Phone(305) 918-1980FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-154.69% Return on Assets-130.66% Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.13 per share Price / Book0.69Miscellaneous Outstanding Shares58,280,000Free Float45,625,000Market Cap$45.46 million OptionableNot Optionable Beta1.22 Key ExecutivesMark Richard DybulExecutive Vice Chairman & Chief Executive OfficerFrançois BinetteChief Operating OfficerLuisa PucheChief Financial Officer & SecretaryGreg DuczynskiSenior Vice President-Clinical OperationsJoseph R. CohenDirector-Research & DiscoveryKey CompetitorsAnebulo PharmaceuticalsNASDAQ:ANEBBiora TherapeuticsNASDAQ:BIORHomology MedicinesNASDAQ:FIXXPraxis Precision MedicinesNASDAQ:PRAXHCW BiologicsNASDAQ:HCWBView All CompetitorsInstitutional OwnershipTwo Sigma Advisers LPSold 21,700 shares on 5/15/2023Ownership: 0.101%Two Sigma Investments LPSold 33,515 shares on 5/15/2023Ownership: 0.101%Belvedere Trading LLCSold 24,300 shares on 5/15/2023Ownership: 0.000%BlackRock Inc.Bought 154,743 shares on 5/12/2023Ownership: 2.212%HRT Financial LPBought 38,712 shares on 5/12/2023Ownership: 0.069%View All Institutional Transactions ENOB Stock - Frequently Asked Questions How have ENOB shares performed in 2023? Enochian Biosciences' stock was trading at $1.03 at the beginning of 2023. Since then, ENOB stock has decreased by 24.3% and is now trading at $0.78. View the best growth stocks for 2023 here. Are investors shorting Enochian Biosciences? Enochian Biosciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,430,000 shares, a decrease of 6.5% from the April 30th total of 1,530,000 shares. Based on an average daily volume of 58,400 shares, the days-to-cover ratio is presently 24.5 days. Currently, 5.3% of the company's stock are short sold. View Enochian Biosciences' Short Interest. When is Enochian Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, June 2nd 2023. View our ENOB earnings forecast. What other stocks do shareholders of Enochian Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enochian Biosciences investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and What is Enochian Biosciences' stock symbol? Enochian Biosciences trades on the NASDAQ under the ticker symbol "ENOB." Who are Enochian Biosciences' major shareholders? Enochian Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.21%), Two Sigma Advisers LP (0.10%), Two Sigma Investments LP (0.10%), HRT Financial LP (0.07%) and Belvedere Trading LLC (0.00%). Insiders that own company stock include Carl Forest Sandler and Serhat Gumrukcu. View institutional ownership trends. How do I buy shares of Enochian Biosciences? Shares of ENOB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enochian Biosciences' stock price today? One share of ENOB stock can currently be purchased for approximately $0.78. How much money does Enochian Biosciences make? Enochian Biosciences (NASDAQ:ENOB) has a market capitalization of $45.46 million. The company earns $-113,430,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. How can I contact Enochian Biosciences? Enochian Biosciences' mailing address is 2080 Century Park EastSuite 906, Los Angeles CA, 90067. The official website for the company is www.enochianbio.com. The company can be reached via phone at (305) 918-1980 or via email at ir@enochianbio.com. This page (NASDAQ:ENOB) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enochian Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.